Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Objective: To investigate whether syngeneic BM-derived DCs generated in vitro and fused with syngeneic C1498 tumor cells (murine AML line) could induce a better antitumor protective effect compared to similarly generated DCs pulsed with C1498 lysate with or without co-injection of a class B CpG oligodeoxynucleotide (CpG 7909) in vivo. Methods: DCs were pulsed with C1498 lysate prior to intravenous administration 14 and 7 days prior to tumor challenge. Separate cohorts received DCs electrically fused to irradiated C1498 cells. Cohorts were administered DCs that were lysate-pulsed or fused with tumor cells on days 14 and 7 prior to tumor injection. Some cohorts were co-injected with CpG 7909 at the time of DC administration. Results: All DC vaccines significantly improved survival (p < 0.01) vs nonvaccinated controls. There was no difference in the antitumor protective response between mice that received pulsed vs fused DCs (47% vs 45% survival). Both DC vaccines generated a fivefold increase in splenic tumor-reactive cytotoxic T-lymphocyte precursor cells and significantly (p < 0.05) higher mean frequencies of IFN-γ-producing splenocytes compared to controls. CpG 7909 improved the survival of mice receiving the fused DCs (p < 0.05) but not the pulsed DCs. Surviving mice were rechallenged and found to be resistant to lethal tumor injection. Conclusions: DC vaccine strategies may be effective in generating anti-AML responses. No advantage was observed between lysate-pulsed and tumor cell-fused DCs. CpGs may provide an adjuvant effect depending on the type of DC vaccine administered.

Original languageEnglish (US)
Pages (from-to)1403-1412
Number of pages10
JournalExperimental Hematology
Issue number10
StatePublished - Oct 2006

Bibliographical note

Funding Information:
The authors would like to thank Greg Veltri of the University of Minnesota Cancer Center's Flow Cytometry Core Laboratory for the multispectral flow analysis and LeAnn Oseth from the University of Minnesota Cytogenetics Laboratory for the FISH analysis. The authors would also like to thank Stacy Bohl for her technical assistance. Supported in part by grants from the Children's Cancer Research Fund, Viking Children's Fund, Coley Pharmaceutical Group, and NIH grants R01 CA-72669 (BRB) and R01 CA-85922 (WC).


Dive into the research topics of 'Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses'. Together they form a unique fingerprint.

Cite this